Monoclonal anti-human IgG is the antibody specific for the lateral flow immunoassay development, for dengue rapid test.
IgG antibody was purified from mouse ascitic fluids by Protein-A chromatography.
Immunoglobulin G (IgG) is a type of antibody that plays a crucial role in the immune response by identifying and neutralizing foreign objects such as bacteria and viruses. Mouse anti-human IgG antibodies are monoclonal or polyclonal antibodies produced in mice that specifically target human IgG molecules. These antibodies are widely used in research, diagnostics, and therapeutic applications.
IgG is the most abundant antibody isotype found in human serum, comprising about 75% of the total immunoglobulin content. It consists of four subclasses: IgG1, IgG2, IgG3, and IgG4, each with distinct biological properties. The basic structure of an IgG molecule includes two heavy chains and two light chains, forming a Y-shaped structure. The variable regions at the tips of the Y allow the antibody to bind specifically to antigens.
Mouse anti-human IgG antibodies are generated by immunizing mice with human IgG or its fragments. The immune system of the mouse recognizes the human IgG as a foreign antigen and produces antibodies against it. These antibodies can be harvested from the mouse serum or produced using hybridoma technology, where B cells from the immunized mouse are fused with myeloma cells to create hybrid cells that can produce large quantities of the desired antibody.
Mouse anti-human IgG antibodies are characterized by their high specificity and affinity for human IgG. They can be monoclonal, derived from a single B cell clone, or polyclonal, derived from multiple B cell clones. Monoclonal antibodies offer high specificity, while polyclonal antibodies provide a broader range of reactivity.
One of the main challenges in using mouse anti-human IgG antibodies is the potential for immunogenicity when used in human patients. The human immune system may recognize the mouse-derived antibodies as foreign and mount an immune response against them. To mitigate this, antibodies can be humanized or fully human antibodies can be developed.